WO2022062357A1 - 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物 - Google Patents

一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物 Download PDF

Info

Publication number
WO2022062357A1
WO2022062357A1 PCT/CN2021/084889 CN2021084889W WO2022062357A1 WO 2022062357 A1 WO2022062357 A1 WO 2022062357A1 CN 2021084889 W CN2021084889 W CN 2021084889W WO 2022062357 A1 WO2022062357 A1 WO 2022062357A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
independently
lrrk2
disease
Prior art date
Application number
PCT/CN2021/084889
Other languages
English (en)
French (fr)
Inventor
谢伟东
程星
Original Assignee
广州智睿医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州智睿医药科技有限公司 filed Critical 广州智睿医药科技有限公司
Publication of WO2022062357A1 publication Critical patent/WO2022062357A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • the invention belongs to the field of medicine, in particular to a medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity.
  • the protein encoded by the LRRK2 gene includes a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, an MLK-domain, and a WD40 domain.
  • LRR leucine-rich repeat
  • LRRK2 kinase activity with Parkinson's disease PD susceptibility, and pathogenic mutations in the LRRK2 gene (especially the most common Gly2019Ser mutation) increase LRRK2 kinase activity and decrease GTP hydrolysis rates in cells and tissues
  • Blocking these activities with small-molecule LRRK2 kinase inhibitors can also provide neuroprotection in certain models of PD, a finding that makes LRRK2 the most promising target for the treatment of Parkinson's disease (PD) disease (Tolosa et al., Nature Reviews in Neurology, Vol.16, 2020, PP.97-10; Paisan-Ruiz et al., J.
  • LRRK2 was identified as a gene potentially associated with elevated susceptibility to Crohn's disease and susceptibility to leprosy (Zhang et al., New England J. Med., Vol. 361, 2009, pp. 2609- 2618; Barrett et al, Nature Genetics, Vol. 40, 2008, pp.
  • LRRK2 is also associated with the following conditions: Alzheimer's transformation from mild cognitive impairment (WO2007149798); L-dopa-induced dyskinesia (Hurley et al., Eur.J, Neurosci., Vol.26, 2007, pp. 171-177); CNS disorders associated with neuroblastoid proliferation and migration, and modulation of LRRK2 may be used to improve neural outcomes and neuronal damage following ischemic injury (such as ischemic stroke, traumatic brain injury or Stimulation of CNS functional recovery after spinal cord injury) (Milosevic et al., Neurodegen., Vol. 4, 2009, 25; Zhang et al., J. Neurosci. Res, Vol. 88, 2010, pp. 3275-3281).
  • ischemic injury such as ischemic stroke, traumatic brain injury or Stimulation of CNS functional recovery after spinal cord injury
  • Cancers such as kidney cancer, breast cancer, prostate cancer (eg solid tumors), blood and lung cancer and acute myeloid leukemia (AML) (WO2011038572); lymphoma and leukemia (Ray et al., J. Immunolo., Vol. 230, 2011, 109); papillary renal and thyroid cancer (Brendan D Looyenga et al., Proc Natl Acad Sci U S A, Vol. 108(4), 2011, pp.
  • Immune system diseases including rheumatoid arthritis, systemic lupus erythematosus, autoimmune hemolytic anemia, pure erythropoiesis, idiopathic thrombocytopenic purpura (ITP), Evans syndrome, Vasculitis, bullous skin disease, type I diabetes, Sjogren's syndrome, Delvic's disease, and inflammatory diseases (Nakamura et al., DNA Res., Vol. 13(4) , 2006, pp. 169-183; Engel et al., Pharmacol. Rev., Vol.
  • Lung diseases such as chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (Araya et al., Intern. Med., Vol. 52, 2013, 2295-2303).
  • small molecules of LRRK2 kinase Inhibitors can also be used to increase the host's therapeutic response to a range of intracellular bacterial, parasitic, and viral infections, including diseases such as tuberculosis (Rubinsztein et al., Nat.
  • Alzheimer's disease and other neurodegenerative diseases (Nixon, Nat. Med. , Vol. 19, 2013, pp. 983-97) and Gaucher disease (Westbroek et al., Trends. Mol. Med., Vol. 17, 2011, 485-493); tauopathy characterized by hyperphosphorylation of Tau , such as argillophilic granulosis, Pick's disease (P ick's disease), corticobasal degeneration, progressive supranuclear palsy, and hereditary frontotemporal dementia and Parkinson's disease associated with chromosome 17 (Jakes R et al., Biochemicaet Biophysica Acta, Vol. 1739, 2005, pp. 240-250); microglial pro-inflammatory responses (Moehle et al., J. Neuroscience, Vol. 32, 2012, pp. 1602-1611).
  • compounds that effectively modulate LRRK2 activity can provide treatment for diseases or conditions mediated by LRRK2, including neurodegenerative diseases, cancer, inflammatory diseases, bacterial and viral infections, and other diseases.
  • the purpose of the present invention is to overcome the shortcomings of the prior art and provide a medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity.
  • the present invention provides a medicine for the treatment or prevention of diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity, comprising LRRK2 inhibitor, and the LRRK2 inhibitor includes the compound represented by Chemical formula 1, its optical isomer. , at least one of its prodrugs, its salts, its hydrates, its solvates, its N-oxides, its deuterated analogs;
  • L 1 , L 2 , L 3 , L 4 are independently C, O or N;
  • a 2 is -H, -OH, halogen, -CN, nitro, -NH 2 , -NHArCH 2 A a ,
  • a 3 is independently unsubstituted, -H, -Ar(CH 2 ) n A a , or
  • a 4 is independently -H, keto or
  • a 5 is independently unsubstituted, -H, substituted or unsubstituted C 3-10 cycloalkyl, or containing at least one unsubstituted or substituted 3- to 8-membered ring heterocycloalkyl group selected from N and O heteroatoms, wherein C 3-10 cycloalkyl and 3- to 8-membered ring heterocycloalkyl groups are substituted, the substituent is at least one of OH, -(CH 2 ) n OH, -NH 2 , and C 1-10 hydrocarbon groups,
  • a 3 and A 4 are connected to form an unsubstituted or substituted 5- to 8-membered heterocyclic aryl group containing at least one N, wherein when the 5- to 8-membered heterocyclic aryl group is substituted, the substituents are -OH, halogen, -CN, nitro, -NH2 , C1-10 hydrocarbyl, substituted or unsubstituted C3-10 cycloalkyl, unsubstituted or substituted 5- to 8-membered containing at least one heteroatom selected from N and O at least one of cycloheterocycloalkyl,
  • a 4 is connected with A 5 to form unsubstituted or substituted aryl;
  • each n is independently an integer from 0 to 6;
  • Each A a is independently represented as -H, substituted or unsubstituted C 3-6 cycloalkyl or epoxyalkyl, substituted or unsubstituted C 1-10 straight or branched chain alkyl, or contains at least one Unsubstituted or substituted 5- to 8-membered ring heterocycloalkyl selected from N and O heteroatoms, wherein substitution in A is substituted by at least one of the following substituents: C 1-10 hydrocarbyl, halogen, methoxy , amino, -COCH 2 OH;
  • a b is represented by -H, substituted or unsubstituted unsaturated 1,6-naphthyridine, substituted or unsubstituted C 3-10 cycloalkyl, wherein the substitution in A b is substituted by at least one of the following substituents: C 1 -10 Hydrocarbyl, halogen, methoxy, amino, -COCH 2 OH;
  • a c is represented as -H, benzodioxane or benzazepine
  • a d represents one of the following unsubstituted or substituted groups: aryl, heterocyclyl, wherein the substitution in A d is substituted by at least one of the following substituents: -H, alkyl, -CN, halogen, haloalkyl , hydroxyl, mercapto, alkoxy, alkylthio, alkoxyalkyl, aralkyl, diarylalkyl, aryl, heterocyclic;
  • a e represents one of the following unsubstituted or substituted groups: alkylene, -C(O)N-, -C(O)-, -NHC(O)-, alkylene-C(O)- , -C(O)-alkylene, alkylene C(O)-alkylene, -NC(O)NH-, wherein substitution in A e is substituted by at least one of the following substituents: -H, alkane group, -CN, halogen, haloalkyl, hydroxyl, mercapto, alkoxy, alkylthio, alkoxyalkyl, aralkyl, diarylalkyl, aryl, heterocyclyl;
  • a f represents one of the following unsubstituted or substituted groups: C3-10 cycloalkyl, 3- to 8-membered cyclic heterocycloalkyl containing at least one heteroatom selected from N and O, wherein A f is substituted by Substituted with at least one of the following substituents: -H, alkyl, -CN, halo, haloalkyl, hydroxy, mercapto, alkoxy, alkylthio, alkoxyalkyl, aralkyl, diarylalkyl , aryl, heterocyclyl.
  • the structural formula of the compound represented by the chemical formula 1 is as follows:
  • the L 3 is C or N;
  • the A 1 is -H, a ketone group, -NH(CH 2 ) n A a , or NHA b ;
  • the A 2 is -H, -NH 2 , -NHArCH 2 A a , or
  • the A 3 is independently unsubstituted, -H, or -Ar(CH 2 ) n A a
  • the A 4 is independently -H, or A 3 is linked to A 4 to form an unsubstituted containing at least one N Or substituted 5- to 8-membered heterocyclic aryl;
  • the A 5 is an unsubstituted, -H, substituted or unsubstituted C 3-10 cycloalkyl, or contains at least one heteroatom selected from N and O.
  • each A is independently represented as -H, substituted or unsubstituted C 3-6 cycloalkyl or epoxyalkyl, or contains at least one selected from N and O heteroatom unsubstituted or substituted 5- to 8-membered ring heterocycloalkyl, wherein the substitution in A a is substituted by at least one of the following substituents: C 1-10 hydrocarbyl, amino;
  • a b is represented as substituted or Unsubstituted unsaturated 1,6-naphthyridine, substituted or unsubstituted C 3-10 cycloalkyl, wherein substitution in A b is substituted by at least one of the following substituents: C 1-10 hydrocarbyl, amino, -COCH 2 oh.
  • the A 1 is -H, a ketone group
  • the A 2 is -H, -NH 2
  • the A is independently unsubstituted, -H or
  • the A 4 is independently -H, or
  • a 3 is connected with A 4 to form
  • the A 5 is -H,
  • the structural formula of the compound represented by the chemical formula 1 is as follows:
  • the L 3 and L 4 are independently N, C or O; the A 1 is -H, -O(CH 2 ) n A a , -(CH 2 ) n A a , or The A 2 is -H or The A 3 is unsubstituted, -H, or The A4 is independently -H or The A 5 is independently unsubstituted, -H or Or A 4 is connected with A 5 to form an unsubstituted or substituted aryl group; each A a is independently represented as an unsubstituted or substituted C 3-6 cycloalkyl, or an unsubstituted or substituted C 3-6 cycloalkyl group containing at least one heteroatom selected from N and O Substituted or substituted 5- to 8-membered ring heterocycloalkyl, wherein the substitution in A a is substituted by at least one of the following substituents: amino, -COCH 2 OH; A c is represented by benzo
  • the A 1 is -H, -OCH 3
  • the A 2 is -H or The A 3 has no substituent, -H or
  • the A4 is independently -H, or
  • the A 5 is independently unsubstituted, -H, or Alternatively A 4 is linked to A 5 to form an unsubstituted phenyl group.
  • the compound represented by the chemical formula 1 is any one of the following compounds:
  • the disease includes at least one of neurodegenerative disease, precancerous conditions and cancer, autoimmune disease, inflammation.
  • the disease comprises Alzheimer's disease, L-dopa-induced dyskinesia, Parkinson's disease, enhanced cognitive memory, central nervous system disorders, dementia, amyotrophic lateral sclerosis, kidney disease Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Papillary Cancer, Lung Cancer, Acute Myeloid Leukemia, Multiple Myeloma, Leprosy, Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis, Muscular Atrophic Lateral At least one of sclerosis, rheumatoid arthritis, or ankylosing spondylitis.
  • the dotted line in the six-membered ring or the five-membered ring in the chemical formula 1 indicates that the double bond is optional. If the double bond exists, its position is also uncertain, and other similar descriptions express the same meaning; above;
  • the hydrocarbon groups include alkyl groups and unsaturated hydrocarbon groups, such as alkenyl groups; the above halogens include F, Cl, Br, etc.;
  • the atoms of the 3- to 8-membered ring also contain at least one heteroatom among N and O, and the 3- to 8-membered ring is unsubstituted or substituted by a substituent.
  • a 3 is connected with A 4 to form an unsubstituted or substituted 5- to 8-membered heterocyclic aryl group containing at least one N, that is, the atoms constituting the 5- to 8-membered ring contain at least one N atom in addition to carbon atoms, And the 5- to 8-membered ring is unsubstituted or substituted by a substituent;
  • Ar represents an aryl group, such as phenyl, naphthyl, etc.;
  • a 5 is independently unsubstituted, -H, substituted or unsubstituted C 3-10 cycloalkyl, or contains at least one heteroatom selected from N and O unsubstituted or substituted 3- to 8-membered ring heterocycloalkyl, which means that A 5 is independently an unsubstituted, -H, substituted C 3-10 ring Alkyl, unsubstituted C 3-10 cycloalkyl, An unsubsubstituted
  • the beneficial effect of the present invention lies in that: the medicine of the present invention contains a specific LRRK2 inhibitor, which can effectively treat or prevent diseases related to the activity of LRRK2 kinase or any of its mutants (such as LRRK2 mutant G2019S).
  • Parkinson's disease and other Lewy body diseases including diffuse Lewy body disease, Lewy body variant of Alzheimer's disease, combined Parkinson's disease and Alzheimer's disease Merger's disease, multiple system atrophy and dementia with Lewy bodies, etc.
  • cancers such as kidney cancer, breast cancer, prostate cancer, blood cancer, papilloma, lung cancer, acute myeloid leukemia, multiple myeloid tumor, melanoma, etc.
  • autoimmune diseases and inflammations such as leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid joints inflammation or ankylosing spondylitis.
  • Fig. 1 is the kinase biological activity Kd curve of LRRK2 WT and LRRK2 G2019S determined by the compound of Example 1 through Experimental Example 13;
  • Figure 2 is the kinase biological activity Kd curve of LRRK2 WT and LRRK2 G2019S determined by the compound of Example 4 by Experimental Example 13;
  • Figure 3 is the kinase biological activity Kd curves of LRRK2 WT and LRRK2 G2019S determined by the compound of Example 7 by Experimental Example 13;
  • Figure 4 is the kinase bioactivity Kd curves of LRRK2 WT and LRRK2 G2019S determined by Experimental Example 13 for the compound of Example 8.
  • the present invention relates to a medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity, comprising an LRRK2 inhibitor, the LRRK2 inhibitor comprising a compound represented by Chemical Formula 1, its optical isomer, its prodrug, its At least one of pharmaceutically acceptable salts, hydrates, solvates, N-oxides, deuterated analogs thereof.
  • the compound represented by Chemical Formula 1 can be used for the prevention and treatment of LRRK2 or related disorders caused by abnormal LRRK2 mutations, such as Alzheimer's disease, L-dopa-induced dyskinesia, Parkinson's disease, dementia, muscle Atrophic lateral sclerosis, kidney cancer, breast cancer, prostate cancer, blood cancer, papilloma, lung cancer, acute myeloid leukemia, multiple myeloma, leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colon inflammation, amyotrophic lateral sclerosis, rheumatoid arthritis, ankylosing spondylitis, etc.
  • LRRK2 or related disorders caused by abnormal LRRK2 mutations such as Alzheimer's disease, L-dopa-induced dyskinesia, Parkinson's disease, dementia, muscle Atrophic lateral sclerosis, kidney cancer, breast cancer, prostate cancer, blood cancer, papilloma, lung cancer, acute myeloid leukemia, multiple myel
  • the compound represented by Chemical Formula 1 can be used for the prevention and treatment of diseases or conditions mediated at least in part by LRRK2 or abnormal LRRK2 mutations as neurodegenerative diseases, for example, central nervous system (CNS) disorders such as Parkinson's disease (PD).
  • diseases or conditions mediated at least in part by LRRK2 or abnormal LRRK2 mutations as neurodegenerative diseases, for example, central nervous system (CNS) disorders such as Parkinson's disease (PD).
  • CNS central nervous system
  • PD Parkinson's disease
  • AD Alzheimer's disease
  • dementia including Lewy body dementia and vascular dementia
  • amyotrophic lateral sclerosis ALS
  • age-related memory impairment mild cognitive impairment ( For example, including transition from mild cognitive impairment to Alzheimer's disease), argillophilic granulosa disease, lysosome disease (eg, Niemann-Pick type C, Gaucher disease), corticobasal degeneration , progressive supranuclear palsy, hereditary frontal dementia and Parkinson's disease (FTDP-17) associated with chromosome 17, withdrawal symptoms/relapse associated with drug addiction, L-dopa-induced Dyskinesia, Huntington's Disease (HD) and HIV-Associated Dementia (HAD).
  • the disorder is an ischemic disease of organs including, but not limited to, the brain, heart, kidneys, and liver.
  • the compound represented by Chemical Formula 1 for the treatment of a disease or condition mediated at least in part by LRRK2 or aberrant LRRK2 mutation is cancer, such as thyroid cancer, kidney cancer (including papillary kidney cancer), breast cancer, lung cancer, Blood and prostate cancers (eg solid tumors), leukemias (including acute myeloid leukemia (AML) or lymphomas.
  • cancer such as thyroid cancer, kidney cancer (including papillary kidney cancer), breast cancer, lung cancer, Blood and prostate cancers (eg solid tumors), leukemias (including acute myeloid leukemia (AML) or lymphomas.
  • the compound of Formula 1 for use in the treatment of a disease or condition mediated at least in part by LRRK2 or aberrant LRRK2 mutation is an inflammatory disorder.
  • Inflammatory disorders are inflammatory bowel diseases, such as Crohn's disease or ulcerative colitis (the two are commonly referred to together as inflammatory bowel disease).
  • the inflammatory disease is leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis or ankylosing spondylitis.
  • the compound represented by Chemical Formula 1 is used to treat other diseases mediated at least in part by LRRK2 or aberrant LRRK2 mutations: multiple sclerosis, systemic lupus erythematosus, autoimmune hemolytic anemia, pure erythropoiesis, Idiopathic thrombocytopenic purpura (ITP), Ivan's syndrome, vasculitis, bullous skin disease, type 1 diabetes, Sugarcan's syndrome, Dewk's disease, and inflammatory myopathy.
  • diseases mediated at least in part by LRRK2 or aberrant LRRK2 mutations multiple sclerosis, systemic lupus erythematosus, autoimmune hemolytic anemia, pure erythropoiesis, Idiopathic thrombocytopenic purpura (ITP), Ivan's syndrome, vasculitis, bullous skin disease, type 1 diabetes, Sugarcan's syndrome, Dewk's disease, and inflammatory myopathy.
  • the compound represented by Chemical Formula 1 may be used in the form of a pharmaceutically acceptable salt thereof.
  • the pharmaceutically acceptable salt may be an acid addition salt formed from a pharmaceutically acceptable free acid.
  • Acid addition salts can be obtained from inorganic acids (such as hydrochloric, nitric, phosphoric, sulfuric, bromic, hydroiodic, nitrous, phosphorous, etc.), non-toxic organic acids (such as aliphatic mono- and dicarboxylates, benzene alkanoates, hydroxyalkanoates and alkanoates, aromatic acids, aliphatic and aromatic sulfonic acids, etc.) or organic acids (e.g.
  • Acid addition salts can be obtained from pharmaceutically non-toxic salts including sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate , metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, octanoate, acrylate, formate, isobutyric acid Salt, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate , Butyne-1,4-Dioleate, Hexane
  • the acid addition salt can be prepared by a conventional method, for example, by dissolving the compound represented by Chemical Formula 1 or a derivative thereof in an organic solvent such as methanol, ethanol, acetone, dichloromethane or acetonitrile, and adding an organic solvent thereto acid or mineral acid to obtain a precipitate, which is then filtered and dried, or the solvent and excess acid are subjected to vacuum distillation, drying and then crystallization in the presence of an organic solvent.
  • an organic solvent such as methanol, ethanol, acetone, dichloromethane or acetonitrile
  • the compound represented by Chemical Formula 1 can be prepared and used in the form of a pharmaceutically acceptable metal salt thereof.
  • the alkali metal or alkaline earth metal salt can be obtained by, for example, dissolving the compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating the filtrate to dryness.
  • sodium, potassium or calcium salts are pharmaceutically suitable as metal salts.
  • the corresponding salts can be obtained by reacting alkali metal or alkaline earth metal salts with suitable silver salts such as silver nitrate.
  • the compound represented by Chemical Formula 1 can be at least one of its pharmaceutically acceptable deuterated analogs, prodrugs, stereoisomers, its salts, its hydrates, its solvates, and its N-oxides preparation and use in the form of species.
  • the compound represented by Chemical Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof may be administered in a single dose or multiple doses at the time of clinical administration.
  • the medicaments of the present invention can be administered using a variety of methods including, for example, rectal, pulmonary, oral, buccal, intranasal, and transdermal routes.
  • the drug may be administered by intraarterial injection, intravenous, intraperitoneal, enteral, parenteral, intramuscular, subcutaneous, oral, topical, or inhalation form.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc., can be used in the preparation of the pharmaceutical preparation of the present invention.
  • Examples of the medicament of the present invention as preparations for oral administration include tablets, pills, hard/soft capsules, liquids, suspensions, emulsions, syrups, granules, elixirs, lozenges and the like.
  • these formulations may contain diluents (eg lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine) or lubricants (eg silicon dioxide, talc, stearic acid and its magnesium or calcium salts and/or polyethylene glycol).
  • Tablets may contain binders such as magnesium aluminum silicate, starch paste, gelatin, methyl cellulose, sodium carboxymethyl cellulose, polyethylene collidine, and the like, and may optionally contain disintegrating agents such as starch , agar, alginic acid or its sodium salt, or boiling mixture) absorbent, coloring agent, flavoring agent, sweetening agent, etc.
  • binders such as magnesium aluminum silicate, starch paste, gelatin, methyl cellulose, sodium carboxymethyl cellulose, polyethylene collidine, and the like
  • disintegrating agents such as starch , agar, alginic acid or its sodium salt, or boiling mixture) absorbent, coloring agent, flavoring agent, sweetening agent, etc.
  • One mode of administration of the medicament of the present invention is parenteral, such as by injection, which can be made into an aqueous or oily suspension or emulsion, containing one of sesame oil, corn oil, cottonseed oil, peanut oil and an elixir, mannose alcohol and dextrose, or sterile aqueous solutions and similar pharmaceutical vehicles.
  • the medicament of the present invention when used by inhalation or insufflation, it may include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, and powders.
  • Liquid or solid pharmaceuticals may contain suitable pharmaceutically acceptable excipients as described herein.
  • the drug is administered by oral or nasal respiratory route for local or systemic effect.
  • the drug in a pharmaceutically acceptable solvent can be nebulized by use of an inert gas. Nebulized solutions can be inhaled directly from the nebulizing device or the nebulizing device can be attached to a mask holder or intermittent positive pressure breathing machine. It may be a solution, suspension or powder composition suitable for administration by a delivery device, preferably oral or nasal.
  • the present invention relates to a pharmaceutical kit for preventing or treating LRRK2 or related disorders caused by abnormal LRRK2 mutation
  • the kit comprises a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt, deuterated analog, interconversion Isomers, stereoisomers, mixtures of stereoisomers, prodrugs, or deuterated analogs, and labels and/or instructions for use of the compounds for therapeutic indications, including diseases or conditions described herein.
  • the containers can be vials, jars, ampoules, prefilled syringes, and intravenous bags.
  • the compound represented by Chemical Formula 1 may be administered in combination with other agents including (but not limited to): compounds that are apoptosis inhibitors, PARP poly(ADP-ribose) polymerization Enzyme inhibitors, Src inhibitors, agents for the treatment of vascular diseases, hypertension, hypercholesterolemia and type II diabetes, anti-inflammatory agents, anti-embolic agents, fibrinolytic agents, anti-platelet agents, lipid-lowering agents , direct thrombin inhibitors, glycoprotein IIb/IIla receptor inhibitors, calcium channel blockers, beta-adrenergic receptor blockers, cyclooxygenases (eg, COX-1 and COX-2 ) inhibitors, angiotensin system inhibitors (eg, angiotensin-converting enzyme (ACE) inhibitors), renin inhibitors, and/or that bind to cell adhesion molecules and inhibit the ability of white blood cells to attach to such molecules
  • agents including (but not limited to): compounds that are apoptosis inhibitors,
  • the compounds of the present disclosure can be administered in combination with additional agents that are active in the treatment of neurodegenerative diseases.
  • the compounds may be administered in combination with one or more additional therapeutic agents useful in the treatment of Parkinson's disease.
  • the additional therapeutic agent is L-dopa (eg, sinemet CR), a dopamine agonist (eg, Ropinerol or Pramipexole), catechol -O-methyltransferase (COMT) inhibitors (eg, Entacapone), L-monoamine oxidase (MAO) inhibitors (eg, selegiline or rasagiline ( rasagiline) or an agent that increases dopamine release (eg, Zonisamide).
  • L-dopa eg, sinemet CR
  • a dopamine agonist eg, Ropinerol or Pramipexole
  • catechol -O-methyltransferase (COMT) inhibitors eg, Entacapone
  • LRRK2G2019S enzyme substrate (LRRK peptide), ATP, TR-FRET diluent buffer, pLRRK peptide antibody, 384-well assay plate, and DMSO.
  • Detection reaction conditions 1 ⁇ diluent buffer, 10 mM EDTA, 2 nM antibody, 23 °C reaction temperature, 10 ⁇ L total reaction volume.
  • 5 ⁇ L of the test solution was transferred to the assay plate, and the untreated blank control wells containing 5 ⁇ L of DMSO and the control group 5 ⁇ L of the DMSO solution of the known inhibitor comparative example were successively added to the source plate (384-well assay plate, Labcyte). The plates were centrifuged at 2500 rpm for 1 minute and sealed with foil.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种治疗或预防与LRRK2激酶或异常LRRK2突变激酶活性相关疾病的药物，属于医药领域。所述药物包括化学式1表示的化合物、其光学异构体、其前体药物、其盐、其水合物、其溶剂化物、其N-氧化物、其氘化类似物中的至少一种，对LRRK2激酶或异常LRRK2突变激酶具有很好的抑制作用，能用于治疗或预防与LRRK2激酶或异常LRRK2突变激酶活性相关疾病，例如阿兹海默氏症、L多巴诱发性运动障碍、帕金森氏病、痴呆症、肾癌、乳腺癌、前列腺癌、血癌、乳头状瘤、肺癌、急性骨髓性白血病、多发性骨髓瘤、麻风病、克罗恩氏病、炎症性肠病、溃疡性结肠炎、肌肉萎缩性侧索硬化、类风湿性关节炎或强直性脊椎炎。

Description

一种治疗或预防与LRRK2激酶或异常LRRK2突变激酶活性相关疾病的药物 技术领域
本发明属于医药领域，具体涉及一种治疗或预防与LRRK2激酶或异常LRRK2突变激酶活性相关疾病的药物。
背景技术
LRRK2基因编码的蛋白包括一个富含亮氨酸重复(LRR)结构域，激酶结构域，一个DFG样基序，一个RAS域，一个GTP酶域，MLK-域，和WD40结构域。很多遗传和生化证据证明LRRK2激酶活性与帕金森病PD易感性有关，LRRK2基因的致病性突变(特别是最常见的Gly2019Ser突变)会增加细胞和组织中的LRRK2激酶活性和GTP水解速率降低，在某些PD模型中，小分子LRRK2激酶抑制剂会阻断这些活动还可以提供神经保护作用，这一发现使LRRK2已成为治疗帕金森病(PD)疾病最有希望的靶标(Tolosa等，Nature Reviews in Neurology，Vol.16，2020，PP.97-10；Paisan-Ruiz等，J.Parkinson's Disease，Vol.3，2013，pp.85-103；Guo等，Experimental Cell Research，Vol.313(16)，2007，pp.3658-3670；Andrew B.West，Experimental Neurology，Vol.298，2017，pp.236-245)。LRRK2被鉴别为潜在地与升高的对克罗恩氏病的易感性和对麻风病的易感性相关的基因(Zhang等，New England J.Med.，Vol.361，2009，pp.2609-2618；Barrett等,Nature Genetics，Vol.40，2008，pp.955-962)；还与脊椎强直(ankyIosing spondylytis)(Danoy等，PLoS Genetics，Vol 6(12)，2010，pp.1-5)和肌萎缩侧索硬化(Shtilans等，Amyotrophic lateral Sclerosis，2011，pp.1-7)相关。
LRRK2还与以下病症相关:自轻度认知障得到阿兹海默氏症转化(WO2007149798)；L-多巴诱发性运动障碍(Hurley等，Eur.J,Neurosci.，Vol.26，2007，pp.171-177)；与神经母细胞增生和迁移相关联的CNS病症，并且LRRK2的调节可用于缺血性损伤后改良神经效果和神经元损伤(诸如缺血性中风、创伤性脑损伤或脊髓损伤)后刺激CNS官能复原(Milosevic等，Neurodegen.，Vol.4，2009，25；Zhang等，J.Neurosci.Res，Vol.88，2010，pp.3275-3281)。其他相关疾病：包括糖尿病、肥胖症、运动神经元疾病、癫痫症和一些癌症(Rubinsztein等，Nat.Rev.Drug Discovery，Vol.11，2012，709-730)。癌症如肾癌、乳腺癌、前列腺癌(例如实体肿瘤)、血癌和肺癌以及急性髓性白血病(AML)(WO2011038572)；淋巴瘤和白血病(Ray等，J.Immunolo.，Vol.230，2011，109)；乳头状肾癌和甲状腺癌(Brendan D Looyenga等，Proc Natl Acad Sci U S A，Vol.108(4)，2011，pp.1439-44)；多发性骨髓瘤(Chapman等，Nature，Vol.471，2011，pp.467-472)。免疫系统疾病：包括类风湿性关节炎、全身性红斑性狼疮症、自体免疫溶血性贫血、纯红细胞形成不全、特发性血小板减少性紫癜(ITP)、伊凡氏症候群((Evans syndrome)、血管炎、大疱性皮肤病、I型糖尿病、休格连氏症候群(Sjogren's syndrome)、德维克氏病(Delvic's disease)和炎症性疾病(Nakamura等，DNA Res.，Vol.13(4)，2006，pp.169-183；Engel等，Pharmacol.Rev.，Vol.63，2011，127-156；Homam等，J.Clin.Neuromuscular Disease，Vol.12，2010，pp.91-102)。肺部疾病如慢性阻塞性肺病和特发性肺纤维化(Araya等，Intern.Med.，Vol.52，2013，2295-2303)。作为自噬和吞噬过程的启动子，LRRK2激酶的小分子抑制剂也可用于增加宿主对一系列细胞内细菌感染、寄生虫感染和病毒感染(包括诸如结核病等疾病)的治疗反应(Rubinsztein等，Nat.Rev.，2012，709-730；Araya等，Intern.Med.，Vol.52，2013，95-2303；Gutierrez，Biochemical Society Conference，Leucine rich repeat kinase2:ten years along the road to therapeutic intervention,Henley Business School，UK 12 July 2016)、HIV、西尼罗病毒和切昆贡亚病毒(Shoji-Kawata等，Nature，Vol.494，2013，pp.201-206)。也用于其他a-突触核蛋白病(Orenstein等，Nature Neurosci.，Vol.16，2013，394-406)、Tau蛋白病(Li等，Neurodegen.Dis.，Vol.7，2010，pp.265-271)、阿尔茨海默氏病和其他神经变性疾病(Nixon，Nat.Med.，Vol.19，2013，pp.983-97)和戈谢病(Westbroek等，Trends.Mol.Med.，Vol.17，2011，485-493)；特征在于Tau的过磷酸化的tau蛋白病，诸如嗜银颗粒病、皮克氏病(Pick's disease)、皮质基底核退化症、进行性核上麻痹以及与染色体17相关联的遗传性额颞叶型痴呆和帕金森氏症(Jakes R等，Biochemicaet Biophysica Acta，Vol.1739,2005，pp.240-250)；小神经胶质促炎性反应(Moehle等，J.Neuroscience，Vol.32，2012，pp.1602-1611)。
因此，有效调节LRRK2活性的化合物可以提供由LRRK2介导的疾病或病状为神经退化疾病、癌症、炎症性疾病、细菌和病毒感染、以及其它疾病的治疗。
发明内容
本发明的目的在于克服现有技术存在的不足之处而提供一种治疗或预防与LRRK2激酶或异常LRRK2突变激酶活性相关疾病的药物。
为实现上述目的，本发明提供了一种治疗或预防与LRRK2激酶或异常LRRK2突变激酶活性相关疾病的药物，含有LRRK2抑制剂，所述LRRK2抑制剂包括化学式1表示的化合物、其光学异构体、其前体药物、其盐、其水合物、其溶剂化物、其N-氧化物、其氘化类似物中的至少一种；
[化学式1]
Figure PCTCN2021084889-appb-000001
在化学式1中，L 1、L 2、L 3、L 4独立地为C、O或N；
A 1为-H、酮基、C 1-10烃基、-O(CH 2) nA a、-NH(CH 2) nA a、-(CH 2) nA a、-NHSO 2CH＝CH 2、NHA b、或
Figure PCTCN2021084889-appb-000002
A 2为-H、-OH、卤素、-CN、硝基、-NH 2、-NHArCH 2A a、
Figure PCTCN2021084889-appb-000003
A 3独立地为无取代基、-H、-Ar(CH 2) nA a、或
Figure PCTCN2021084889-appb-000004
A 4独立地为-H、酮基或
Figure PCTCN2021084889-appb-000005
A 5独立地为无取代基、-H、取代或未取代的C 3-10环烷基、
Figure PCTCN2021084889-appb-000006
Figure PCTCN2021084889-appb-000007
或含有至少一个选自N和O杂原子未取代或取代的3至8元环杂环烷基，其中C 3-10环烷基以及3至8元环杂环烷基被取代时，取代基为OH、-(CH 2) nOH、-NH 2、C 1-10烃基中的至少一种，
或者A 3与A 4连接形成含有至少一个N的未取代或取代的5至8元杂环环芳基，其中5至8元杂环环芳基被取代时，取代基为-OH、卤素、-CN、硝基、-NH 2、C 1-10烃基、取代或未取代的C 3-10环烷基、含有至少一个选自N和O杂原子的未取代的或取代的5至8元环杂环烷基中的至少一种，
或者A 4与A 5连接形成未取代或取代的芳基；
每个n均独立地为0至6的整数；
每个A a独立地表示为-H、取代或未取代的C 3-6环烷基或环氧烷基、取代或未取代的C 1-10直链或支链烷基、或含有至少一个选自N和O杂原子的未取代的或取代的5至8元环杂环烷基，其中A a中的取代由以下至少一种取代基取代：C 1-10烃基、卤素、甲氧基、氨基、-COCH 2OH；
A b表示为-H、取代或未取代不饱和1,6-萘啶、取代或未取代的C 3-10环烷基，其中A b中的取代由以下至少一种取代基取代：C 1-10烃基、卤素、甲氧基、氨基、-COCH 2OH；
A c表示为-H、苯并二氧杂环或苯并氮杂环；
A d表示以下未取代或取代基团中的一种：芳基、杂环基，其中A d中的取代由以下至少一种取代基取代：-H、烷基、-CN、卤素、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基、杂环基；
A e表示以下未取代或取代基团中的一种：亚烷基、-C(O)N-、-C(O)-、-NHC(O)-、亚烷基-C(O)-、-C(O)-亚烷基、亚烷基C(O)-亚烷基、-NC(O)NH-，其中A e中的取代由以下至少一种取代基取代：-H、烷基、-CN、卤素、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基、杂环基；
A f表示以下未取代或取代基团中的一种：C3-10环烷基、含有至少一个选自N和O杂原子的3至8元环杂环烷基，其中A f中的取代由以下至少一种取代基取代：-H、烷基、-CN、卤紊、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基、杂环基。
优选地，所述化学式1表示的化合物的结构式如下所示：
Figure PCTCN2021084889-appb-000008
进一步优选地，所述L 3为C或N；所述A 1为-H、酮基、-NH(CH 2) nA a、或NHA b；所述A 2为-H、-NH 2、-NHArCH 2A a、或
Figure PCTCN2021084889-appb-000009
所述A 3独立地为无取代基、-H、或-Ar(CH 2) nA a，所述A 4独立地为-H，或者A 3与A 4连接形成含有至少一个N的未取代或取代的5至8元杂环环芳基；所述A 5为无取代基、-H、取代或未取代的C 3-10环烷基、或含有至少一个选自N和O杂原子未取代或取代的3至8元环杂环烷基；每个A a独立地表示为-H、取代或未取代的C 3-6环烷基或环氧烷基、或含有至少一个选自N和O杂原子的未取代的或取代的5至8元环杂环烷基，其中A a中的取代由以下至少一种取代基取代：C 1-10烃基、氨基；A b表示为取代或未取代不饱和1,6-萘啶、取代或未取代的C 3-10环烷基，其中A b中的取代由以下至少一种取代基取代：C 1-10烃基、氨基、-COCH 2OH。
更进一步优选地，所述A 1为-H、酮基、
Figure PCTCN2021084889-appb-000010
所述A 2为-H、-NH 2、
Figure PCTCN2021084889-appb-000011
所述A 3独立地为无取代基、 -H或
Figure PCTCN2021084889-appb-000012
所述A 4独立地为-H，或者A 3与A 4连接形成
Figure PCTCN2021084889-appb-000013
所述A 5为-H、
Figure PCTCN2021084889-appb-000014
Figure PCTCN2021084889-appb-000015
优选地，所述化学式1表示的化合物的结构式如下所示：
Figure PCTCN2021084889-appb-000016
进一步优选地，所述L 3、L 4独立地为N、C或O；所述A 1为-H、-O(CH 2) nA a、-(CH 2) nA a、或
Figure PCTCN2021084889-appb-000017
所述A 2为-H或
Figure PCTCN2021084889-appb-000018
所述A 3为无取代基、-H、或
Figure PCTCN2021084889-appb-000019
所述A 4独立地为-H或
Figure PCTCN2021084889-appb-000020
所述A 5独立地为无取代基、-H或
Figure PCTCN2021084889-appb-000021
或者A 4与A 5连接形成未取代或取代的芳基；每个A a独立地表示为未取代或取代的C 3-6环烷基、或含有至少一个选自N和O杂原子的未取代或取代的5至8元环杂环烷基，其中A a中的取代由以下至少一种取代基取代：氨基、-COCH 2OH；A c表示为苯并二氧杂环。
更进一步优选地，所述A 1为-H、-OCH 3、
Figure PCTCN2021084889-appb-000022
Figure PCTCN2021084889-appb-000023
所述A 2为-H或
Figure PCTCN2021084889-appb-000024
所述A 3无取代基、-H或
Figure PCTCN2021084889-appb-000025
所述A 4独立地为-H、或
Figure PCTCN2021084889-appb-000026
所述A 5独立地为无取代基、-H、或
Figure PCTCN2021084889-appb-000027
或者A 4与A 5连接形成未取代苯基。
优选地，所述化学式1表示的化合物为以下化合物中的任意一种：
(1)4-[2-(丁胺基)-5-[4-[(4-甲基哌嗪-1-基)甲基]苯基]吡咯[2,3-d]嘧啶-7-基]环己-1-醇；
(2)4-[2-(2-环丙基氨基)-5-[4-[(4-甲基哌嗪-1-基)甲基]苯基]吡咯[2,3-d]嘧啶-7-基]环己-1-醇；
(3)2-羟基-1-[2-[[8-(4-甲基环己基)-4,6,8,11-四氮杂三环[7.4.0.02,7]十三碳-1(9)，2,4,6,10,12-己-5-基]氨基]-7,8-二氢-5H-1,6-萘啶-6-基]乙酮；
(4)N-[4-[(4-甲基哌嗪-1-基)甲基]苯基]-4-(7H吡咯[2,3-d]嘧啶-4-基氨基)-1H-吡唑-5-甲酰胺；
(5)2-N-(4-氨基环己基)-9-环戊基-6-N-[4-(吗啉-4-基甲基)苯基]嘌呤-2,6-二胺；
(6)6-氨基-9-[(2R，3R，4S，5R)-3,4-二羟基-5-(羟甲基)氧代-2-基]-1H-嘌呤-2-酮；
(7)1-[2-[5-[(3-甲基氧乙烷-3-基)甲氧基]苯并咪唑-1-基]喹啉-8-基]哌啶-4-胺；
(8)1-环丙基-3-[5-[6-(吗啉-4-基甲基)-1H-苯并咪唑-2-基]-1H-吡唑-4-基]脲；
(9)N-(1,3-苯并二恶唑-5-基甲基)-4-([1]苯并呋喃[3,2-d]嘧啶-4-基)哌嗪-1-碳硫酰；
(10)N-(5-叔丁基-1,3,4-噻二唑-2-基)-1-[2-(5-甲氧基-1H-吲哚-3-基)乙基]-5-氧吡咯烷-3-羧酰胺；
(11)N-[5-(1,3-苯并二恶唑-5-基)-1H-吡唑-3-基]-4-[(1-甲基哌啶-4-基)氨基]苯甲酰胺；
(12)N-[2-(二乙氨基)乙基]-5-[(Z)-[5-(乙烯基磺酰基氨基)-2-氧代-1H-吲哚-3-亚烷基]甲基]-2,4-二甲基-1H-吡咯-3-羧酰胺。
优选地，所述疾病包括神经退化性疾病、癌前病状和癌症、自身免疫性病、炎症中的至少一种。
优选地，所述疾病包括阿兹海默氏症、L-多巴诱发性运动障得、帕金森氏病、增强认知记忆、中枢神经系统病症、痴呆症、肌萎缩侧索硬化症、肾癌、乳腺癌、前列腺癌、血癌、乳头状癌、肺癌、急性骨髓性白血病、多发性骨髓瘤、麻风病、克罗恩氏病、炎症性肠病、溃疡性结肠炎、肌肉萎缩性侧索硬化、类风湿性关节炎或强直性脊椎炎中的至少一种。
另外需要说明的是，化学式1中六元环或五元环中的虚线表示的是双键可有可无，如果双键存在，其位置也不确定，其他类似描述所表达的意思相同；以上烃基均包括烷基以及不饱和烃基，如烯基；以上卤素均包括F、Cl、Br等；以上选自N和O杂原子未取代或取代的3至8元环杂环烷基是指构 成3至8元环的原子除碳原子外，还含有N、O中至少一种杂原子，且该3至8元环未被取代或被取代基取代，其他类似描述所表达的意思类似，如A 3与A 4连接形成含有至少一个N的未取代或取代的5至8元杂环环芳基，即是指构成5至8元环的原子除碳原子外，还含有至少一个N原子，且该5至8元环未被取代或被取代基取代；Ar表示芳基，如苯基、萘基等；A 5独立地为无取代基、-H、取代或未取代的C 3-10环烷基、
Figure PCTCN2021084889-appb-000028
或含有至少一个选自N和O杂原子未取代或取代的3至8元环杂环烷基，指的是A 5独立地为无取代基、-H、有取代基的C 3-10环烷基、无取代基的C 3-10环烷基、
Figure PCTCN2021084889-appb-000029
含有至少一个选自N和O杂原子无取代基的3至8元环杂环烷基、或含有至少一个选自N和O杂原子有取代基的3至8元环杂环烷基，其他类似描述同理；A d表示以下未取代或取代基团中的一种：芳基、杂环基，其中A d中的取代由以下至少一种取代基取代：-H、烷基、-CN、卤素、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基、杂环基，这句话指的是A d表示为无取代基的芳基、无取代基的杂环基、有取代基的芳基、或有取代基的杂环基，其中有取代基的芳基是指芳基被-H、烷基、-CN、卤素、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基、杂环基中的至少一种取代，有取代基的杂环基指的是杂环基被-H、烷基、-CN、卤素、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基、杂环基中的至少一种取代。
相比现有技术，本发明的有益效果在于：本发明药物包含特定的LRRK2抑制剂，能有效治疗或预防与LRRK2激酶或其任意突变体(如LRRK2突变体G2019S)活性相关疾病，如可用于预防和治疗神经变性疾病，诸如帕金森病和其它雷维小体型疾病，包括弥散性雷维小体疾病、阿尔茨海默氏病的雷维小体变型、复合的帕金森病和阿尔茨海默氏病、多系统萎缩和痴呆伴雷维小体等；也可用于预防和治疗癌症，诸如肾癌、乳腺癌、前列腺癌、血癌、乳头状瘤、肺癌、急性骨髓性白血病、多发性骨髓瘤、黑素瘤等；还可用于预防和治疗自身免疫疾病和炎症，诸如麻风病、克罗恩氏病、炎症性肠病、溃疡性结肠炎、肌肉萎缩性侧索硬化、类风湿性关节炎或强直性脊椎炎。
附图说明
图1是实施例1化合物通过实验实施例13测定的LRRK2 WT和LRRK2 G2019S的激酶生物活性Kd曲线；
图2是实施例4化合物通过实验实施例13测定的LRRK2 WT和LRRK2 G2019S的激酶生物活性Kd曲线；
图3是实施例7化合物通过实验实施例13测定的LRRK2 WT和LRRK2 G2019S的激酶生物活性Kd曲线；
图4是实施例8化合物通过实验实施例13测定的LRRK2 WT和LRRK2 G2019S的激酶生物活性Kd曲线。
具体实施方式
为更好的说明本发明的目的、技术方案和优点，下面将结合具体实施例对本发明作进一步说明。
本发明涉及一种治疗或预防与LRRK2激酶或异常LRRK2突变激酶活性相关疾病的药物，含有LRRK2抑制剂，该LRRK2抑制剂包括化学式1表示的化合物、其光学异构体、其前体药物、其药学上可接受的盐、其水合物、其溶剂化物、其N-氧化物、其氘化类似物中的至少一种。
根据本发明，化学式1表示的化合物可用于预防和治疗LRRK2或异常LRRK2突变引起的相关的病症，例如阿兹海默氏症、L多巴诱发性运动障碍、帕金森氏病、痴呆症、肌肉萎缩性侧索硬化、肾癌、乳腺癌、前列腺癌、血癌、乳头状瘤、肺癌、急性骨髓性白血病、多发性骨髓瘤、麻风病、克罗恩氏病、炎症性肠病、溃疡性结肠炎、肌肉萎缩性侧索硬化、类风湿性关节炎、强直性脊椎炎等。
根据本发明，化学式1表示的化合物可用于预防和治疗至少部分由LRRK2或异常LRRK2突变介导的疾病或病状为神经退化疾病，例如，中枢神经系统(CNS)病症(诸如帕金森氏病(PD)、阿兹海默氏病(AD))、痴呆症(包括路易体性痴呆和血管性痴呆)、肌肉萎缩性侧索硬化(ALS)、年龄相关记忆功能障得、轻度认知障碍(例如，包括自轻度认知障碍转变至阿兹海默氏症)、嗜银颗粒病、溶嗨体病(例如，C型尼曼一皮克病、高歇病)、皮质基底核退化症、进行性核上麻痹、与染色体17相关联的遗传性额题叶型痴呆和帕金森氏症(FTDP-17)、与药物成瘾相关联的停药症状/复发、L-多巴诱发性运动障得、亨廷顿氏病(HD)和HIV关联性痴呆症(HAD)。病症为包括(但不限于)大脑、心脏、肾脏和肝脏的器官的缺血性疾病。
在一些实施方案中，化学式1表示的化合物用于治疗至少部分由LRRK2或异常LRRK2突变介导的疾病或病状为癌症，如甲状腺癌、肾癌(包括乳头状肾癌)、乳腺癌、肺癌、血癌和前列腺癌(例如实体肿瘤)、白血病(包括急性骨髓性白血病(AML)或淋巴瘤。
在另一些实施方案中，化学式1表示的化合物用于治疗至少部分由LRRK2或异常LRRK2突变介导的疾病或病状为炎症性病症。炎症性病症为炎症性肠疾病，诸如克罗恩氏病或溃疡性结肠炎(两者一般一起称为炎症性肠病)。炎症性疾病为麻风病、克罗恩氏病、炎症性肠病、溃疡性结肠炎、肌肉萎缩性侧索硬化、类风湿性关节炎或强直性脊椎炎。
在其它实施方案中，化学式1表示的化合物用于治疗至少部分由LRRK2或异常LRRK2突变介导的其它疾病：多发性硬化症、全身性红斑狼疮症、自体免疫溶血性贫血、纯红细胞形成不全、特发性血小板减少性紫癜(ITP)、伊凡氏症候群、血管炎、大疱性皮肤病、1型糖尿病、休格连氏症候群、德维克氏病和炎症性肌病。
根据本发明，化学式1表示的化合物可以以其药学上可接受的盐的形式使用。这里，药学上可接受的盐可为药学上可接受的游离酸形成的酸加成盐。酸加成盐可获自无机酸(例如盐酸、硝酸、磷酸、硫酸、溴酸、氢碘酸、亚硝酸、亚磷酸等)、无毒有机酸(例如脂肪族单一和二羧酸酯、苯基取代的链烷酸酯、羟基链烷酸酯和链烷酸酯、芳香酸、脂肪族和芳香族磺酸等)或有机酸(例如乙酸、苯甲酸、柠檬酸、乳酸、马来酸葡萄糖酸、甲磺酸、4-甲苯磺酸、酒石酸、富马酸等)。酸加成盐可获自药学上无毒的盐，包括硫酸盐、焦硫酸盐、硫酸氢盐、亚硫酸盐、亚硫酸氢盐、硝酸盐、磷酸盐、磷酸一氢盐、磷酸二氢盐、偏磷酸盐、焦磷酸盐、氯化物、溴化物、碘化物、氟化物、乙酸盐、丙酸盐、癸酸盐(decanoate)、辛酸盐、丙烯酸盐、甲酸盐、异丁酸盐、癸酸盐(caprate)、庚酸盐、丙炔酸盐、草酸盐、丙二酸盐、琥珀酸盐、辛二酸盐、癸二酸盐、富马酸盐、马来酸盐、丁炔-1,4-二油酸盐、己烷-1,6油酸盐、苯甲酸盐、氯苯甲酸盐、苯甲酸甲酯、二硝基苯甲酸盐、羟苤酸盐、甲苯基苯甲酸盐邻苯二甲酸盐、对苯二甲酸盐、苯磺酸盐、甲苯磺酸盐、氯苯磺酸盐、二甲苯磺酸盐、苯基乙酸盐、苯基丙酸盐、苯基丁酸盐、柠檬酸盐、乳酸盐，β-羟基丁酸盐、乙醇酸盐、马来酸盐、酒石酸盐、甲磺酸盐、丙磺酸盐、萘-1-磺酸盐、禁-2-磺酸盐、扁桃酸盐等。
根据本发明，酸加成盐可以通过常规方法制备，例如，通过将化学式1表示的化合物或其衍生物溶解在有机溶剂如甲醇、乙醇、丙酮、二氯甲烷或乙腈中，并向其中加入有机酸或无机酸以获得沉淀物，然后将沉淀物过滤并干燥，或者将溶剂和过量的酸进行真空蒸馏、干燥然后在有机溶剂存在下结晶。
另外，根据本发明，化学式1表示的化合物可以以其药学上可接受的金属盐的形式制备和使用。具体地，碱金属或碱土金属盐可通过以下方法获得：例如将化合物溶解在过量的碱金属氢氧化物或碱土金属氢氧化物溶液中，过滤未溶解的化合物盐，并将滤液蒸发至干。这里，钠盐、钾盐或钙盐作为金属盐是药学上合适的。此外，相应的盐可通过使碱金属或碱土金属盐与合适的银盐(例如硝酸银)反应来获得。
根据本发明，化学式1表示的化合物可以以其药学上可接受的氘化类似物、前药、立体异构体、其盐、其水合物、其溶剂化物、其N-氧化物中的至少一种的形式制备和使用。
在根据本发明的药物中，化学式1表示的化合物、其光学异构体或其药学上可接受的盐可在临床给药时以单一剂量或多剂量形式施用。本发明药物可利用各种方法施用，所述方法包括例如经直肠、肺部、口服、口腔、鼻内和经皮途径。在某些实施方案中，药物可通过动脉内注射、静脉内、腹膜内、经肠、非经肠、肌肉内、皮下、经口、局部或以吸入剂形式施用。
本发明药物制剂制备时可使用常用的稀释剂或赋形剂，如填充剂、增量剂、粘合剂、润湿剂、崩解剂、表面活性剂等。
本发明药物用作口服给药制剂的实例包括片剂、丸剂、硬/软胶囊、液体、悬浮液、乳液、糖浆、颗粒、酏剂、锭剂等。除了活性成分外，这些制剂可含有稀释剂(如乳糖、右旋糖、蔗糖、甘露醇、山梨糖醇、纤维素和/或甘氨酸)或润滑剂(如二氧化硅、滑石、硬脂酸及其镁盐或钙盐和/或聚乙二醇)。片剂可含有粘合剂，例如硅酸镁铝、淀粉糊、明胶、甲基纤维素、羧甲基纤维素钠和聚乙烯叱咯烷等，并且可任选地含有崩解剂(例如淀粉、琼脂、海藻酸或其钠盐、或沸腾混合物)吸收剂、着色剂、调味剂、甜味剂等。
本发明药物的一种施用模式为非经肠，例如通过注射，可将其制成水性或油性悬浮液或乳液，含有芝麻油、玉米油、棉籽油、花生油中的一种以及酏剂、甘露糖醇和右旋糖，或无菌水溶液和类似医药媒剂。
本发明药物以吸入或吹入方式使用时，可包括溶液和悬浮液的药学上可接受的水性溶剂或有机溶剂或其混合物以及散剂。液体或固体药物可含有如本文中所描述的适合的药学可接受的赋形剂。在一些实施方案中，针对局部或全身性作用，通过经口或经鼻呼吸道途径施用药物。在其它实施方案中，药学上可接受的溶剂中的药物可通过使用惰性气体进行雾化。雾化溶液可直接自雾化装置吸入或雾化装置可连接到面罩托或间歇性正压呼吸机。可以是适合递送装置施用(优选经口或经鼻)的溶液、悬浮液或粉末组合物。
此外，本发明涉及一种用于预防或治疗LRRK2或异常LRRK2突变引起的相关病症的药物试剂盒，试剂盒包括化学式1表示的化合物或其药学上可接受的盐、氘化类似物、互变异构体、立体异构体、立体异构体的混合物、前药或氘化类似物，和使用所述化合物治疗适应症(包括本文所述的疾病或病状)的标签和/或说明。包括处于适合容器中的本文中所描述的化合物或其药学上可接受的盐、氘化类似物、互变异构体、立体异构体、立体异构体混合物、前药或氘化类似物。容器可为小瓶、广口瓶、安瓿、预装载注射器和静脉内袋。
此外，在本公开的另一方面中，化学式1表示的化合物可与其它药剂组合施用，所述药剂包括(但不限于)：为细胞凋亡抑制剂的化合物、PARP聚(ADP-核糖)聚合酶抑制剂、Src抑制剂、用于治疗血管疾病、高血压、高胆固醇血症和Ⅱ Ⅰ型糖尿病的药剂、抗炎症剂药剂、抗栓塞剂、纤维蛋溶解剂、抗血小板药剂、降脂剂、直接凝血酶抑制剂、糖蛋白IIb/IIla受体抑制剂、钙离子通道阻断剂、B肾上腺素激导性受体阻断剂、环加氧酶(例如，COX-1和COX-2)抑制剂、血管紧张素系统抑制剂(例如，血管收缩素转化酶(ACE)抑制剂)、肾素抑制剂，和/或与细胞粘着分子结合并抑制白血细胞与此类分子连接的能力的药剂(例如，多肽抗体、多克隆抗体和单克隆抗体)。另外，本公开的化合物可与具有治疗神经退化疾病的活性的额外药剂组合施用。举例来说，在一些实施方案中，化合物可与适用于治疗帕金森氏病的一或多种额外治疗剂组合施用。在一些实施方案中，额外治疗剂为L-多巴(例如，sinemet CR)、多巴胺激导性促效剂(例如，罗宾奈索(Ropinerol)或普拉克索(Pramipexole))、儿茶酚-0-甲基转移酶(COMT)抑制剂(例如恩他卡朋(Entacapone))、L-单胺氧化酵素(MAO)抑制剂(例如，司来吉兰(selegiline)或雷沙吉兰(rasagiline))或增加多巴胺释放的药剂(例如，唑尼沙胺(Zonisamide))。
实施例1
参考专利WO2013052417A1制备4-[2-(丁胺基)-5-[4-[(4-甲基哌嗪-1-基)甲基]苯基]吡咯[2,3-d]嘧啶-7-基]环己-1-醇，其结构式如下：
Figure PCTCN2021084889-appb-000030
实施例2
参考专利WO2013052417A1制备4-[2-(2-环丙基氨基)-5-[4-[(4-甲基哌嗪-1-基)甲基]苯基]吡咯[2,3-d]嘧啶-7-基]环己-1-醇，其结构式如下：
Figure PCTCN2021084889-appb-000031
实施例3
参考专利WO2012129344A1制备2-羟基-1-[2-[[8-(4-甲基环己基)-4,6,8,11-四氮杂三环[7.4.0.02,7]十三碳-1(9)，2,4,6,10,12-己-5-基]氨基]-7,8-二氢-5H-1,6-萘啶-6-基]乙酮，其结构式如下：
Figure PCTCN2021084889-appb-000032
实施例4
参考专利WO2014108053A1制备N-[4-[(4-甲基哌嗪-1-基)甲基]苯基]-4-(7H吡咯[2,3-d]嘧啶-4-基氨基)-1H-吡唑-5-甲酰胺，其结构式如下：
Figure PCTCN2021084889-appb-000033
实施例5
参考专利WO2018171819A1制备2-N-(4-氨基环己基)-9-环戊基-6-N-[4-(吗啉-4-基甲基)苯基]嘌呤-2,6-二胺，其结构式如下：
Figure PCTCN2021084889-appb-000034
实施例6
参考专利WO9312130A1制备备6-氨基-9-[(2R，3R，4S，5R)-3,4-二羟基-5-(羟甲基)氧代-2-基]-1H-嘌呤-2-酮，其结构式如下：
Figure PCTCN2021084889-appb-000035
实施例7
参考专利WO2004020431 A2制备1-[2-[5-[(3-甲基氧乙烷-3-基)甲氧基]苯并咪唑-1-基]喹啉-8-基]哌啶-4-胺，其结构式如下：
Figure PCTCN2021084889-appb-000036
实施例8
参考专利WO 2008001115A2制备1-环丙基-3-[5-[6-(吗啉-4-基甲基)-1H-苯并咪唑-2-基]-1H-吡唑-4-基]脲，其结构式如下：
Figure PCTCN2021084889-appb-000037
实施例9
参考专利WO2005037825A2制备N-(1,3-苯并二恶唑-5-基甲基)-4-([1]苯并呋喃[3,2-d]嘧啶-4-基)哌嗪-1-碳硫酰，其结构式如下：
Figure PCTCN2021084889-appb-000038
实施例10
在Vitas-M Laboratory购买N-(5-叔丁基-1,3,4-噻二唑-2-基)-1-[2-(5-甲氧基-1H-吲哚-3-基)乙基]-5-氧吡咯烷-3-羧酰胺，货号为STK288775，其结构式如下：
Figure PCTCN2021084889-appb-000039
实施例11
参考(European Journal of Medicinal Chemistry)(2019),176,248-267制备N-[5-(1,3-苯并二恶唑-5-基)-1H-吡唑-3-基]-4-[(1-甲基哌啶-4-基)氨基]苯甲酰胺，其结构式如下：
Figure PCTCN2021084889-appb-000040
实施例12
参考Journal of Medicinal Chemistry(2019),62(5),2428-2446制备N-[2-(二乙氨基)乙基]-5-[(Z)-[5-(乙烯基磺酰基氨基)-2-氧代-1H-吲哚-3-亚烷基]甲基]-2,4-二甲基-1H-吡咯-3-羧酰胺，其结构式如下：
Figure PCTCN2021084889-appb-000041
对比例
参考专利WO2011151360制备[4-[[5-氯-4-(甲基氨基)嘧啶-2-基]氨基]-3-甲氧基苯基]吗啉-4-基甲酮，其结构式如下：
Figure PCTCN2021084889-appb-000042
实施例1至12中制备的化合物的结构示于表1中。
表1
Figure PCTCN2021084889-appb-000043
Figure PCTCN2021084889-appb-000044
实施例13：化合物的生物活性测定
(1)材料
LRRK2G2019S酶、底物(LRRK肽)、ATP、TR-FRET稀释液缓冲液、pLRRK肽抗体、384孔测定培养盘以及DMSO。
(2)酶反应条件：50mM Tris pH7.5、10mM MgCl 2、1mM EGTA、0.01％Brij-35、2mM DTT，5nM LRRK2，134μM ATP，60分钟反应时间，23℃反应温度，10μL总反应体积。
侦测反应条件：1×稀释液缓冲液，10mM EDTA，2nM抗体，23℃反应温度10μL总反应体积。
(3)实验步骤
用100％DMSO溶解稀释测试化合物得到10mM或100μM的储备原液)，以比例为原液体积：缓冲液体积＝1:3.16(20μL+43.2μL)稀释得到最高测试浓度100μM或1μM的待测液。将5μL待测液转移至测定板，未处理的空白对照孔含有5μL DMSO和对照组5μL已知抑制剂比较例的DMSO溶液相继添加到源培养盘(384孔测定培养盘，Labcyte)。将培养盘在2500rpm下离心1分钟并用箔片密封。使用反应缓冲液进行3倍连续稀释以得到11个测试点，并将稀释后100nL的测试化合物溶液、已知抑制剂比较例化合物溶液、DMSO溶液空白组转移至测定培养盘，每个浓度2个复孔。将测定培养盘在2500rpm下离心1分钟，并用箔片密封。
为进行酶反应，将5μL的含5nM LRRK2酶的50mM Tris pH7.5、10mM MgCl2、1mM EGTA、0.01％Brij-35、2mM DTT缓冲液添加到测定培养盘的所有孔。离心培养盘，以将混合物浓缩在孔的底部。在23℃下孵育测定培养盘20分钟。孵育之后，将5μL的1X的激酶反应缓冲液配制2x LRRKtide Substrate和ATP添加到各孔，并离心培养盘以将混合物浓缩在孔的底部。在23℃下孵育培养盘60分钟。
为进行反应的侦测，将10μL包含抗体试剂和10mM EDTA的TR-FRET稀释缓冲液侦测试剂添加到测定培养盘的各孔的所有孔，并离心培养盘以将混合物浓缩在孔的底部。随后，在23℃下孵育培养盘60分钟。使用340m激发滤波器、520nm荧光发射滤波器和490或495nm铽发射滤波器，在TR-FRET模式下的Perkin elmer envision 2104仪器上读取培养盘。变体G2019S LRRK2的抑制作用以完全相同的方法测量。底物ATP和酶的所有最终浓度均相同。
用Graphpad软件进行数据分析，计算得到Kd活性值。
本文中所公开的若干化合物根据上文方法来测试，每个测试浓度为复孔，求平均值，在表2中提供了LRRK2和LRRK2 G2019S相应的Kd活性值。
表2
Figure PCTCN2021084889-appb-000045
Figure PCTCN2021084889-appb-000046
在本说明书和实施例中认定的所有专利和其他出版物明确地为所有目的通过用并入本文。提供这些出版物仅仅是因为它们的公开早于本申请的提交日期。就此而言，绝不应该被解释为承认本发明人无权凭借先有发明或出于任何其他原因在时间上早于这些公开。对于日期的所有陈述或对于这些文件内容的表述是基于本申请人可以获得的信息并且不对所述日期或这些文件的内容的正确性构成任何承认。
最后所应当说明的是，以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制，尽管参照较佳实施例对本发明作了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的实质和范围。

Claims (10)

  1. 一种治疗或预防与LRRK2激酶或异常LRRK2突变激酶活性相关疾病的药物，其特征在于，所述药物含有LRRK2抑制剂，所述LRRK2抑制剂包括化学式1表示的化合物、其光学异构体、其前体药物、其盐、其水合物、其溶剂化物、其N-氧化物、其氘化类似物中的至少一种；
    [化学式1]
    Figure PCTCN2021084889-appb-100001
    在化学式1中，L 1、L 2、L 3、L 4独立地为C、O或N；
    A 1为-H、酮基、C 1-10烃基、-O(CH 2) nA a、-NH(CH 2) nA a、-(CH 2) nA a、-NHSO 2CH＝CH 2、NHA b、或
    Figure PCTCN2021084889-appb-100002
    A 2为-H、-OH、卤素、-CN、硝基、-NH 2、-NHArCH 2A a、
    Figure PCTCN2021084889-appb-100003
    A 3独立地为无取代基、-H、-Ar(CH 2) nA a、或
    Figure PCTCN2021084889-appb-100004
    A 4独立地为-H、酮基或
    Figure PCTCN2021084889-appb-100005
    A 5独立地为无取代基、-H、取代或未取代的C 3-10环烷基、
    Figure PCTCN2021084889-appb-100006
    Figure PCTCN2021084889-appb-100007
    或含有至少一个选自N和O杂原子未取代或取代的3至8元环杂环烷基，其中C 3-10环烷基以及3至8元环杂环烷基被取代时，取代基为OH、-(CH 2) nOH、-NH 2、C 1-10烃基中的至少一种，
    或者A 3与A 4连接形成含有至少一个N的未取代或取代的5至8元杂环环芳基，其中5至8元杂环环芳基被取代时，取代基为-OH、卤素、-CN、硝基、-NH 2、C 1-10烃基、取代或未取代的C 3-10环烷基、含有至少一个选自N和O杂原子的未取代的或取代的5至8元环杂环烷基中的至少一种，
    或者A 4与A 5连接形成未取代或取代的芳基；
    每个n均独立地为0至6的整数；
    每个A a独立地表示为-H、取代或未取代的C 3-6环烷基或环氧烷基、取代或未取代的C 1-10直链或支链烷基、或含有至少一个选自N和O杂原子的未取代的或取代的5至8元环杂环烷基，其中A a中的取代由以下至少一种取代基取代：C 1-10烃基、卤素、甲氧基、氨基、-COCH 2OH；
    A b表示为-H、取代或未取代不饱和1,6-萘啶、取代或未取代的C 3-10环烷基，其中A b中的取代由以下至少一种取代基取代：C 1-10烃基、卤素、甲氧基、氨基、-COCH 2OH；
    A c表示为-H、苯并二氧杂环或苯并氮杂环；
    A d表示以下未取代或取代基团中的一种：芳基、杂环基，其中A d中的取代由以下至少一种取代基取代：-H、烷基、-CN、卤素、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基、杂环基；
    A e表示以下未取代或取代基团中的一种：亚烷基、-C(O)N-、-C(O)-、-NHC(O)-、亚烷基-C(O)-、-C(O)-亚烷基、亚烷基C(O)-亚烷基、-NC(O)NH-，其中A e中的取代由以下至少一种取代基取代：-H、烷基、-CN、卤素、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基、杂环基；
    A f表示以下未取代或取代基团中的一种：C3-10环烷基、含有至少一个选自N和O杂原子的3 至8元环杂环烷基，其中A f中的取代由以下至少一种取代基取代：-H、烷基、-CN、卤紊、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基、杂环基。
  2. 根据权利要求1所述的药物，其特征在于，所述化学式1表示的化合物的结构式如下所示：
    Figure PCTCN2021084889-appb-100008
  3. 根据权利要求2所述的药物，其特征在于，所述L 3为C或N；所述A 1为-H、酮基、-NH(CH 2) nA a、或NHA b；所述A 2为-H、-NH 2、-NHArCH 2A a、或
    Figure PCTCN2021084889-appb-100009
    所述A 3独立地为无取代基、-H、或-Ar(CH 2) nA a，所述A 4独立地为-H，或者A 3与A 4连接形成含有至少一个N的未取代或取代的5至8元杂环环芳基；所述A 5为无取代基、-H、取代或未取代的C 3-10环烷基、或含有至少一个选自N和O杂原子未取代或取代的3至8元环杂环烷基；每个A a独立地表示为-H、取代或未取代的C 3-6环烷基或环氧烷基、或含有至少一个选自N和O杂原子的未取代的或取代的5至8元环杂环烷基，其中A a中的取代由以下至少一种取代基取代：C 1-10烃基、氨基；A b表示为取代或未取代不饱和1,6-萘啶、取代或未取代的C 3-10环烷基，其中A b中的取代由以下至少一种取代基取代：C 1-10烃基、氨基、-COCH 2OH。
  4. 根据权利要求3所述的药物，其特征在于，所述A 1为-H、酮基、
    Figure PCTCN2021084889-appb-100010
    Figure PCTCN2021084889-appb-100011
    所述A 2为-H、-NH 2、
    Figure PCTCN2021084889-appb-100012
    所述 A 3独立地为无取代基、-H或
    Figure PCTCN2021084889-appb-100013
    所述A 4独立地为-H，或者A 3与A 4连接形成
    Figure PCTCN2021084889-appb-100014
    所述A 5为-H、
    Figure PCTCN2021084889-appb-100015
  5. 根据权利要求1所述的药物，其特征在于，所述化学式1表示的化合物的结构式如下所示：
    Figure PCTCN2021084889-appb-100016
  6. 根据权利要求5所述的药物，其特征在于，所述L 3、L 4独立地为N、C或O；所述A 1为-H、-O(CH 2) nA a、-(CH 2) nA a、或
    Figure PCTCN2021084889-appb-100017
    所述A 2为-H或
    Figure PCTCN2021084889-appb-100018
    所述A 3为无取代基、-H、或
    Figure PCTCN2021084889-appb-100019
    所述A 4独立地为-H或
    Figure PCTCN2021084889-appb-100020
    所述A 5独立地为无取代基、-H或
    Figure PCTCN2021084889-appb-100021
    或者A 4与A 5连接形成未取代或取代的芳基；每个A a独立地表示为未取代或取代的C 3-6环烷基、或含有至少一个选自N和O杂原子的未取代或取代的5至8元环杂环烷基，其中A a中的取代由以下至少一种取代基取代：氨基、-COCH 2OH；A c表示为苯并二氧杂环。
  7. 根据权利要求6所述的药物，其特征在于，所述A 1为-H、-OCH 3、
    Figure PCTCN2021084889-appb-100022
    Figure PCTCN2021084889-appb-100023
    所述A 2为-H或
    Figure PCTCN2021084889-appb-100024
    所述A 3无取代基、-H或
    Figure PCTCN2021084889-appb-100025
    所述A 4独立地为-H、或
    Figure PCTCN2021084889-appb-100026
    所述A 5独立地为无取代基、-H、或
    Figure PCTCN2021084889-appb-100027
    或者A 4与A 5连接形成未取代苯基。
  8. 根据权利要求1所述的药物，其特征在于，所述化学式1表示的化合物为以下化合物中的任意一种：
    (1)4-[2-(丁胺基)-5-[4-[(4-甲基哌嗪-1-基)甲基]苯基]吡咯[2,3-d]嘧啶-7-基]环己-1-醇；
    (2)4-[2-(2-环丙基氨基)-5-[4-[(4-甲基哌嗪-1-基)甲基]苯基]吡咯[2,3-d]嘧啶-7-基]环己-1-醇；
    (3)2-羟基-1-[2-[[8-(4-甲基环己基)-4,6,8,11-四氮杂三环[7.4.0.02,7]十三碳-1(9)，2,4,6,10,12-己-5-基]氨基]-7,8-二氢-5H-1,6-萘啶-6-基]乙酮；
    (4)N-[4-[(4-甲基哌嗪-1-基)甲基]苯基]-4-(7H吡咯[2,3-d]嘧啶-4-基氨基)-1H-吡唑-5-甲酰胺；
    (5)2-N-(4-氨基环己基)-9-环戊基-6-N-[4-(吗啉-4-基甲基)苯基]嘌呤-2,6-二胺；
    (6)6-氨基-9-[(2R，3R，4S，5R)-3,4-二羟基-5-(羟甲基)氧代-2-基]-1H-嘌呤-2-酮；
    (7)1-[2-[5-[(3-甲基氧乙烷-3-基)甲氧基]苯并咪唑-1-基]喹啉-8-基]哌啶-4-胺；
    (8)1-环丙基-3-[5-[6-(吗啉-4-基甲基)-1H-苯并咪唑-2-基]-1H-吡唑-4-基]脲；
    (9)N-(1,3-苯并二恶唑-5-基甲基)-4-([1]苯并呋喃[3,2-d]嘧啶-4-基)哌嗪-1-碳硫酰；
    (10)N-(5-叔丁基-1,3,4-噻二唑-2-基)-1-[2-(5-甲氧基-1H-吲哚-3-基)乙基]-5-氧吡咯烷-3-羧酰胺；
    (11)N-[5-(1,3-苯并二恶唑-5-基)-1H-吡唑-3-基]-4-[(1-甲基哌啶-4-基)氨基]苯甲酰胺；
    (12)N-[2-(二乙氨基)乙基]-5-[(Z)-[5-(乙烯基磺酰基氨基)-2-氧代-1H-吲哚-3-亚烷基]甲基]-2,4-二甲基-1H-吡咯-3-羧酰胺。
  9. 根据权利要求1所述的药物，其特征在于，所述疾病包括神经退化性疾病、癌前病状和癌症、自身免疫性病、炎症中的至少一种。
  10. 根据权利要求1所述的药物，其特征在于，所述疾病包括阿兹海默氏症、L-多巴诱发性运动 障得、帕金森氏病、增强认知记忆、中枢神经系统病症、痴呆症、肌萎缩侧索硬化症、肾癌、乳腺癌、前列腺癌、血癌、乳头状癌、肺癌、急性骨髓性白血病、多发性骨髓瘤、麻风病、克罗恩氏病、炎症性肠病、溃疡性结肠炎、肌肉萎缩性侧索硬化、类风湿性关节炎或强直性脊椎炎中的至少一种。
PCT/CN2021/084889 2020-09-28 2021-04-01 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物 WO2022062357A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011045107.X 2020-09-28
CN202011045107.XA CN112043710A (zh) 2020-09-28 2020-09-28 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物

Publications (1)

Publication Number Publication Date
WO2022062357A1 true WO2022062357A1 (zh) 2022-03-31

Family

ID=73605835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/084889 WO2022062357A1 (zh) 2020-09-28 2021-04-01 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物

Country Status (2)

Country Link
CN (1) CN112043710A (zh)
WO (1) WO2022062357A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112043710A (zh) * 2020-09-28 2020-12-08 广州智睿医药科技有限公司 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
CN112695032B (zh) * 2020-12-10 2023-08-11 中国科学院深圳先进技术研究院 一种启动子pLRRK2及其应用
CN116270654A (zh) * 2023-01-20 2023-06-23 首都医科大学宣武医院 Mertk抑制剂在制备治疗阿尔茨海默病药物中的应用
CN116120291B (zh) * 2023-04-11 2023-06-30 英矽智能科技(上海)有限公司 吲唑类化合物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CN103703000A (zh) * 2011-03-23 2014-04-02 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
CN103958510A (zh) * 2011-10-03 2014-07-30 北卡罗来纳大学教堂山分校 用于治疗癌症的吡咯并嘧啶化合物
CN108338985A (zh) * 2017-01-22 2018-07-31 成都中医药大学 巴豆苷的新用途
WO2018171819A1 (en) * 2017-03-20 2018-09-27 Univerzita Palackeho V Olomouci 2,6-disubstituted-9-cyclopentyl-9h-purines, use thereof as medicaments, and pharmaceutical compositions
CN112043710A (zh) * 2020-09-28 2020-12-08 广州智睿医药科技有限公司 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703000A (zh) * 2011-03-23 2014-04-02 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
CN103958510A (zh) * 2011-10-03 2014-07-30 北卡罗来纳大学教堂山分校 用于治疗癌症的吡咯并嘧啶化合物
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CN108338985A (zh) * 2017-01-22 2018-07-31 成都中医药大学 巴豆苷的新用途
WO2018171819A1 (en) * 2017-03-20 2018-09-27 Univerzita Palackeho V Olomouci 2,6-disubstituted-9-cyclopentyl-9h-purines, use thereof as medicaments, and pharmaceutical compositions
CN112043710A (zh) * 2020-09-28 2020-12-08 广州智睿医药科技有限公司 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SMITH GARRICK P., LASSINA BADOLO, VICTORIA CHELL, I-JEN CHEN, KENNETH VIELSTED CHRISTENSEN, LAURENT DAVID, JUSTUS ALFRED DAECHSEL,: "The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 27, 1 August 2017 (2017-08-01), pages 4500 - 4505, XP055914545, DOI: 10.1016/j.bmcl.2017.07.072 *
WAN, Y. C. ET AL.: "Indole: A privileged scaffold for the design of anti-cancer agents.", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY., vol. 183, 11 September 2019 (2019-09-11), XP085892889, DOI: 10.1016/j.ejmech.2019.111691 *

Also Published As

Publication number Publication date
CN112043710A (zh) 2020-12-08

Similar Documents

Publication Publication Date Title
WO2022062357A1 (zh) 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
WO2022062356A1 (zh) 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
JP5399905B2 (ja) セリン−トレオニンタンパク質キナーゼおよびｐａｒｐ調節因子
Huang et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents
CA2760061C (en) Diamino heterocyclic carboxamide compound
WO2017167182A1 (zh) 一种选择性的c-kit激酶抑制剂
WO2017101803A1 (zh) 一种新型egfr和alk激酶的双重抑制剂
US20080299076A1 (en) Compunds and compositions that cause non-apoptotic cell death and uses thereof
BR112013018212A2 (pt) Hidrazida diarila acetileno contendo inibidores de tirosina-cinase
WO2017114383A1 (zh) 一类新型的egfr野生型和突变型的激酶抑制剂
TW201245161A (en) 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
WO2019206069A1 (zh) 一种二芳基巨环化合物、药物组合物以及其用途
EP3870160A1 (en) Compounds and methods to attenuate tumor progression and metastasis
EA026655B1 (ru) 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CN108349974A (zh) 一种取代的吡啶酰胺类化合物及其应用
WO2015058661A1 (zh) Bcr-abl激酶抑制剂及其应用
WO2023083194A1 (zh) Wee1蛋白激酶降解剂及其用途
TWI786303B (zh) 抑制ｃｄｋ4/6活性化合物的晶型及其應用
US20160237061A1 (en) Organic compounds
CN101528704B (zh) 丝氨酸-苏氨酸蛋白激酶和parp调节剂
KR20170095239A (ko) ＰＩ３Ｋβ 저해제로서의 이미다조피리다진 유도체
US11834454B2 (en) Alkynylphenylbenzamide compounds and applications thereof
US20180208566A1 (en) Deuterated Meclizine
US20240150333A1 (en) Taf1 inhibitors
US11542250B2 (en) Inhibitors for the B-catenin/B-cell lymphoma 9 (BCL9) protein-protein interaction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21870746

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21870746

Country of ref document: EP

Kind code of ref document: A1